CompuGroup Medical (COP) Q2 2024 earnings summary

Executive summary

• Preliminary H1 2024 results were released early due to an ad hoc event, with full financials and Q2 details provided.

• Group revenues for H1 2024 were €562m, down 6% year-over-year, with organic revenue growth at -5%; adjusted for prior year one-time effects, organic growth was +1%.

• Recurring revenue share increased to 75% from 67% in the prior year.

• Adjusted EBITDA fell 14% to €114m, and adjusted EPS dropped 24% to €0.81.

• Guidance for 2024 was revised downward due to lower non-recurring revenue and higher investments.

Financial highlights

• Revenues decreased by €33m (-6%) year-over-year in H1 and 9% in Q2, mainly due to one-off effects in Telematics Infrastructure and underlying slowdown.

• Adjusted EBITDA margin for H1 2024 was 20.3% (prior year: 22.4%).

• Free cash flow declined 53% to €39m, and guidance was reduced to €40–60m.

• Adjusted EBITDA guidance for 2024 was lowered by €55m to a new range of €220–250m, reflecting €70m lower revenues and higher investments.

• Adjusted EPS guidance was reduced to €1.55–1.95.

Outlook and guidance

• Organic revenue growth guidance for 2024 was revised from a midpoint of +5% to between -2% and 0%, mainly due to delays in regulatory projects and slower module sales.

• Management expects a stronger H2 2024 and some revival in 2025 as delayed projects like Ségur in France and the Hospital Future Act are realized.

• 2025 guidance will be updated in February 2025, reflecting ongoing uncertainties.

• Segment guidance: AIS now expects organic revenue decline; HIS and PCS expect low to mid-single digit growth.

• Guidance may be affected by delays or changes in Telematics Infrastructure implementation.